In:
Ophthalmic Surgery, Lasers and Imaging Retina, SLACK, Inc., Vol. 48, No. 4 ( 2017-04), p. 326-332
Abstract:
The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of ranibizumab (Lucentis; Genentech, South San Francisco, CA) and to determine potential predictors for early response. PATIENTS AND METHODS: Patients with choroidal neovascularization secondary to AMD were evaluated before and 1 month after their first ranibizumab treatment. Early poor responders were defined as eyes gaining less than five letters 1 month after the first injection. RESULTS: Following the first ranibizumab injection, 58% of 84 patients gained five or more letters. Beyond 42% poor responders, 31% displayed foveal retinal pigment epithelium (RPE) atrophy and 89% a loss of the external limiting membrane (ELM) integrity at baseline. However, the amount of intra- and subretinal fluid, pigment epithelial detachment (PED), and subfoveal fibrosis showed a similar distribution between gainers and poor responders. CONCLUSION: Early poor responders present with more RPE atrophy, as well as a loss of the ELM integrity at baseline optical coherence tomography. [ Ophthalmic Surg Lasers Imaging Retina. 2017;48:326–332.]
Type of Medium:
Online Resource
ISSN:
2325-8160
,
2325-8179
DOI:
10.3928/23258160-20170329-07
Language:
English
Publisher:
SLACK, Inc.
Publication Date:
2017
Permalink